Methods for treating brain cancer using il-13r alpha 2 peptide-based compositions

Patent metadata

Field	Value
Publication number	US-10874730-B2
Application number	US-201514724127-A
Country	US
Kind code	B2
Filing date	May 28, 2015
Priority date	Sep 21, 2004
Publication date	Dec 29, 2020
Grant date	Dec 29, 2020

Abstract

Provided herein are interleukin-13 receptor α2 peptide-based brain cancer vaccines and methods for treating and vaccinating against brain cancer comprising administering to patients in need thereof interleukin-13 receptor α2 peptide-based brain cancer vaccines. Also provided herein are regimens comprising interleukin-13 receptor α2 peptides and at least one additional peptide and/or immunostimulant.

First claim

I claim:

1. A method for treating glioblastoma in a subject in need thereof, wherein the subject has failed prior therapy with temozolomide, radiation therapy, and surgery, the method comprising administering to the subject (a) bevacizumab and (b) a pharmaceutical composition, wherein the pharmaceutical composition is cell-free and comprises 250 to 400 μg of an IL-13Rα2 peptide, 250 to 400 μg of an EphA2 peptide, 250 to 400 μg of a survivin peptide, and 250 to 400 μg of a WT1 peptide; wherein the IL-13Rα2 peptide comprises the amino acid sequence of any one of SEQ ID NOs:1-4, the EphA2 peptide comprises the amino acid sequence of SEQ ID NO:6, the survivin peptide comprises the amino acid sequence of SEQ ID NO:7, and the WT1 peptide comprises the amino acid sequence of SEQ ID NO:8.

2. The method of claim 1 , wherein the pharmaceutical composition further comprises an adjuvant.

3. The method of claim 2 , wherein the adjuvant is Montanide ISA-51.

4. The method of claim 1 , further comprising administering to the subject a helper T cell epitope, wherein the helper T cell epitope is a PADRE peptide, a Tetanus toxoid peptide, or the HBV 128-140 core peptide.

5. The method of claim 1 , further comprising administering to the subject an immune response modifier, wherein the immune response modifier is poly-ICLC or imiquimod.

6. The method of claim 1 , wherein the pharmaceutical composition is administered to the subject subcutaneously or intranodally.

7. The method of claim 1 , wherein the subject is human.

8. A method for treating glioblastoma in a subject in need thereof, wherein the subject has failed prior therapy with temozolomide, radiation therapy, and surgery, the method comprising administering to a subject (a) bevacizumab and (b) a pharmaceutical composition, wherein the pharmaceutical composition is cell-free and comprises 250 to 400 μg of an IL-13Rα2 peptide, 250 to 400 μg of an EphA2 peptide, and 250 to 400 μg of a survivin peptide, wherein the IL-13Rα2 peptide comprises the amino acid sequence of any one of SEQ ID NOs:1-4, the EphA2 peptide comprises the amino acid sequence of SEQ ID NO:6, and the survivin peptide comprises the amino acid sequence of SEQ ID NO:7.

9. The method of claim 8 , wherein the pharmaceutical composition further comprises an adjuvant.

10. The method of claim 9 , wherein the adjuvant is Montanide ISA-51.

11. The method of claim 8 , further comprising administering to the subject a helper T cell epitope, wherein the helper T cell epitope is a PADRE peptide, a Tetanus toxoid peptide, or the HBV 128-140 core peptide.

12. The method of claim 8 , further comprising administering to the subject an immune response modifier, wherein the immune response modifier is poly-ICLC or imiquimod.

13. The method of claim 8 , wherein the pharmaceutical composition is administered to the subject subcutaneously or intranodally.

14. The method of claim 8 , wherein the subject is human.

Assignees

• Univ Of Pittsburgh—Of The Commonwealth System Of Higher Education
• Univ Of Pittsburgh—Of The Commonwealth System

Inventors

• Okada Hideho

Classifications

• A61K40/414

  Nervous system antigens · CPC title

• A61K40/24

  Antigen-presenting cells [APC] · CPC title

• A61K40/19

  Dendritic cells · CPC title

• A61K2239/47

  Brain; Nervous system · CPC title

• A61K38/1709 Primary

  from mammals · CPC title